Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.…
Immuneering Presents Data That Supports Expanding the Clinical Evaluation of Atebimetinib to Anaplastic Thyroid Cancer
Immuneering (NASDAQ: IMRX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 65 employees.
The shares were at 3.380 USD on 20 November 2026, down 50.9% over 52 weeks. Its 52-week range is 3.289 USD to 8.480 USD: the price is 60.1% below the high and 2.8% above the low.
Its market capitalisation is 218.90M USD.
Immuneering reports return on equity of -25.6% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 141.87M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 4 March 2027.